Recomendaciones Del Grupo Español De Investigación En Dermatitis De Contacto Y Alergia Cutánea (Geidac ) De La Aedv En Relación A La Realización De Pruebas Epicutáneas Durante La Pandemia Por Sars-Cov-2 ( Covid-19)

Carrascosa, J M; Pastor-Nieto, M A; Ruiz-Gonzalez, I; Silvestre, J F; Borrego, L; Gatica-Ortega, M E; Gimenez-Arnau, A Mº

Abstract As the COVID-19 pandemic gradually comes under control, the members of the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) have drawn up a proposed list of the requirements, limitations, and conditioning factors affecting the resumption of work in contact dermatitis units. The assumption is that the severe acute respiratory syndrome coronavirus 2 is still circulating and that occasional or seasonal outbreaks will occur. They recommend that the first step should be to assess how many patch tests each clinic can handle and review the waiting list to prioritize cases according to disease severity and urgency. Digital technologies can, where possible, be used to send and receive the documentation necessary for the patch test (information, instructions, informed consent, etc.). If the necessary infrastructure is available, patients can be offered the option of a remote initial consultation. Likewise, in selected cases, the patch test results can be read in a virtual visit using photographs taken by the patient or a video visit can be scheduled to allow the physician to evaluate the site of application remotely. These measures will reduce the number of face-to-face visits required, but will not affect the time spent on each case, which must be scheduled in the normal manner. All of these recommendations are suggestions and should be adapted to the needs and possibilities of each health centre.